

Fine-tuning autophagy in pancreatic adenocarcinoma: full blockage is required

Nicolas Jonckheere, Isabelle Seuningen

► **To cite this version:**

Nicolas Jonckheere, Isabelle Seuningen. Fine-tuning autophagy in pancreatic adenocarcinoma: full blockage is required. *Annals of translational medicine*, AME Publishing Company, 2019, 7 (S1), pp.S43-S43. 10.21037/atm.2019.03.01 . inserm-02341315

HAL Id: inserm-02341315

<https://www.hal.inserm.fr/inserm-02341315>

Submitted on 31 Oct 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Fine-tuning autophagy in pancreatic adenocarcinoma: Full blockage is required.

Nicolas Jonckheere and Isabelle Van Seuningen

Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPARC - Jean-Pierre Aubert Research Center, Team "Mucins, epithelial differentiation and carcinogenesis", F-59000 Lille, France

Correspondence:

nicolas.jonckheere@inserm.fr

Phone: +33 3 20 29 88 65, Fax: +33 3 20 53 85 62

Editorial – Invited by Hailing Lian, science editor from Annals of Translational Medicine

Editorial on the article "**Levels of the Autophagy-Related 5 Protein Affect Progression and Metastasis of Pancreatic Tumors in Mice**" Görgülü et al., *Gastroenterology* 2019

Autophagy is a physiological process of cellular component recycling promoting cell survival and homeostasis under unfavorable conditions. Pancreatic ductal adenocarcinoma (90-95% of pancreatic cancer) has been associated with multiple metabolic alterations including autophagy. Because of its supporting role in tumor growth, inhibition of autophagy has been proposed as a treatment of pancreatic cancer (1,2). Autophagy process is regulated by autophagy-related proteins (ATGs) necessary for the autophagosome formation and subsequent delivering of cytoplasmic content for degradation by lysosomes. Among these proteins, Atg5 is a key player for autophagy onset but little is known about its role in tumorigenesis (3). Ryan's laboratory previously deciphered the roles of Atg5/7 in pancreatic carcinogenesis and notably showed the importance of p53 status (4). They observed that mice lacking Atg5 accumulate low-grade pancreatic intraepithelial neoplasia (PanIN) lesions and that PDAC progression is impaired. Bardhesy's laboratory demonstrated the induction of an autophagy-lysosome gene program regulating metabolic reprogramming in pancreatic adenocarcinoma highlighting the potential of therapeutic lysosome targeting using chloroquine (5).

In the later elegant study, Görgülü and colleagues investigated the dosage sensitive effect of autophagy loss (6). Using GFP-LC3 reporter mice, autophagy was confirmed to occur at every step from acinar-to-ductal metaplasias (ADM), PanINs, pancreatic tumors to metastasis. The authors crossed the prototype mice model expressing oncogenic mutated LstopL-KrasG12D in pancreatic cells (deriving from exocrine Ptf1

cell lineage) with mice carrying conditional disruption of *Atg5* (*Atg5^{flox/flox}*) and compared homozygous (called *A5;Kras*) and heterozygous (called *A5^{+/-};Kras*) with mice harbouring mutated *Kras*^{G12D} (littermates control). Isolated primary tumor cells were characterized regarding their transcriptome or metabolome and more targeting features such as intracellular calcium, activity of extracellular cathepsin, and cell migration/invasion.

As expected, homozygous *A5;Kras* did not develop any advanced tumor. This was consistent with previous observations (4). Strikingly, monoallelic *Atg5* loss (*A5^{+/-};Kras* mice), expressing haploinsufficient *Atg5* levels, did not have an intermediate phenotype but harboured an increased burden of tumors and metastases than control mice (Figure 1A). *In vitro* culture of *A5^{+/-};Kras* cells showed that monoallelic *Atg5* loss led to anoikis resistance, increased migration, invasion and cell spreading. Similar observations were independently obtained using *Atg5*-ShRNA *Kras* cell lines harbouring 58% or 94% *Atg5* relative levels (mimicking *A5^{+/-};Kras* and *A5;Kras* cells, respectively).

Transcriptomic analysis showed that monoallelic *Atg5* loss induced a transcriptional reprogramming with increased expression of genes involved in metabolism, immunity, development, and vesicular trafficking/homeostasis and decreased of adhesion and cell cycle associated cellular functions.

The *A5^{+/-};Kras* pancreas displayed a profound metabolic reprogramming. Indeed, the authors observed elevated amount of oxidative and cell stress associated metabolites. The mitochondrial function and morphology were altered with global decrease of glycolysis, oxidative capacity, acidification rate and ATP turnover in *A5^{+/-}* cells compared with *Kras* controls. Cytoplasmic Ca^{2+} amplitude response and

s100a4 (Ca²⁺ binding protein) were increased in A5+/- cells as well as L- and D-cathepsin activities required for spreading and invasive capacities.

Görgülü and colleagues also investigated the consequence of mono-allelic Atg5 loss on macrophage-mediated inflammation. Cytokine pattern of A5+/- cells was altered with the up-regulation of sets of cytokines involved in macrophage chemoattraction, M2-differentiation and tumor progression/metastasis and decrease of M1 related cytokines. Therefore, A5+/-;Kras cells switched the differentiation pattern from M1 macrophage toward the M2-subtype. M2 macrophages are tumor-associated macrophages (TAM) that contribute to immunosuppressive microenvironment and favor tumor aggressiveness and promote tumor metastasis (7).

Finally, analysis of three independent patient's cohorts (from Munich, Heidelberg and Berlin, Germany) showed a tendency of poorer survival in the group expressing moderate/low ATG5 level compared to high expressing group. Using Survexpress tool (8), we observed an opposite trend when comparing high and low expressing Atg5 patients from PAAD-TCGA (p=0.08; n=176) and PACA-AU-ICGC (p=0.03; n=189) datasets (Figure 1B). In this kind of analysis, it would be interesting to stratify patient with low and moderate autophagy features.

Altogether, this interesting manuscript highlights the critical need of a complete blockage of the autophagy for clinical trials targeting autophagy. Chloroquine (CQ) is approved by the US Food and Drug Administration, FDA and widely employed for the prophylactic malaria medication. The therapeutic potential of chloroquine/Nivaquin has been tested for cancers. Several studies have been conducted for pancreatic adenocarcinoma (Table 1). In regards of the recent findings, the residual activity of autophagy should be evaluated in order to avoid the induction of protumoral immunosuppressive environment described by Algül's laboratory (6).

Acknowledgments: Our work is supported by Inserm and CNRS and grants from la Ligue Nationale Contre le Cancer (Equipe Labellisée Ligue 2010, IVS; Ligue comité 59, 62 IVS, Ligue comité 62, 80 NJ) and by SIRIC ONCOLille, Grant INCaDGOS-Inserm 6041 (NJ, IVS) and by a grant from "Contrat de Plan Etat Région" CPER Cancer 2007-2013 (IVS).

References



1. Yang A, Herter-Sprue G, Zhang H, Lin EY, Biancur D, Wang X, et al. Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms. *Cancer Discov* 2018;8(3):276-87.
2. Boone BA, Zeh HJ, 3rd, Bahary N. Autophagy Inhibition in Pancreatic Adenocarcinoma. *Clin Colorectal Cancer* 2018;17(1):25-31.
3. Liu H, He Z, Simon HU. Protective role of autophagy and autophagy-related protein 5 in early tumorigenesis. *J Mol Med (Berl)* 2015;93(2):159-64.
4. Rosenfeldt MT, O'Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, et al. p53 status determines the role of autophagy in pancreatic tumour development. *Nature* 2013;504(7479):296-300.
5. Perera RM, Stoykova S, Nicolay BN, Ross KN, Fitamant J, Boukhali M, et al. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. *Nature* 2015;524(7565):361-5.
6. Gorgulu K, Diakopoulos KN, Ai J, Schoeps B, Kabacaoglu D, Karpathaki AF, et al. Levels of the Autophagy-Related 5 Protein Affect Progression and Metastasis of Pancreatic Tumors in Mice. *Gastroenterology* 2019;156(1):203-17 e20.
7. Najafi M, Goradel NH, Farhood B, Salehi E, Solhjoo S, Toolee H, et al. Tumor microenvironment: Interactions and therapy. *J Cell Physiol* 2019;234(5):5700-21.
8. Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, Martinez-Torteya A, Chacolla-Huaranga R, Rodriguez-Barrientos A, et al. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. *PLoS One* 2013;8(9):e74250.
9. Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. *Oncologist* 2014;19(6):637-8.
10. Boone BA, Murthy P, Miller-Ocuin J, Doerfler WR, Ellis JT, Liang X, et al. Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. *BMC Cancer* 2018;18(1):678.

Table 1: Autophagy related clinical trials in pancreatic cancer retrieved from ClinicalTrials.gov. Keywords: Chloroquine OR hydroxychloroquine OR Autophagy AND Pancreatic cancer OR Pancreatic adenocarcinoma




ClinicalTrials.gov Identifier	Sponsor	Phase	Title	Description	Associated publications
NCT01506973	Abramson Cancer Center of the University of Pennsylvania	I/II	A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer	Add Hydroxychloroquine (HCQ) to gemcitabine/nab-paclitaxel.	
NCT01273805	Brian Wolpin, MD, MPH, Dana-Farber Cancer Institute	II	Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer	Efficacy of hydroxychloroquine in metastatic pancreatic cancer patients	(9)
NCT01128296	Herbert J. Zeh, III MD, University of Pittsburgh	I	Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas	Safety of hydroxychloroquine in combination with gemcitabine before surgery.	(10)
NCT01978184	Nathan Bahary, MD, University of Pittsburgh	II	Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitaxel With or Without Hydroxychloroquine	Add hydroxychloroquine to pre-operative gemcitabine and nab-paclitaxel	(10)
NCT03344172	Nathan Bahary, MD, University of Pittsburgh	II	Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer (17-134)	Add Avelumab to gemcitabine, nab-paclitaxel and hydroxychloroquine	
NCT01494155	Theodore S Hong, MD. Massachusetts General Hospital	II	Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer	Efficacy of proton/photon beam radiation with hydroxychloroquine and capecitabine	
NCT03825289	University of Utah	II	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer (THREAD)	Escalating doses of hydroxychloroquine (HCQ) combined with trametinib	
NCT01777477	University of Zurich	I	Gemcitabine Combined With Chloroquine in Patients With Metastatic or Unresectable Pancreatic Cancer. A Dose Finding Single Center Phase I Study	Define maximum tolerated dose (MTD) of Chloroquine combined with Gemcitabine	

Figure 1: Atg5 level and pancreatic carcinogenesis (A) Schematic summary of Görgülü manuscript about homozygous and monoallelic loss of Atg5 in Ptf1-Cre;LstopL-KrasG12D mice (B) Overall survival values of Atg5 high/low risk groups in pancreatic adenocarcinoma datasets (PAAD TCGA and PACA-AU – ICGC) analysed by SurvExpress optimized algorithm. Hazard ratio and p-value were determined. The number of analysed patients along time is indicated below the horizontal axis for both conditions.

A



tumor burden



Ptf1-Cre
LSL-KrasG12D
Atg5WT/WT


Ptf1-Cre
LSL-KrasG12D
Atg5lox/lox

Ptf1-Cre
LSL-KrasG12D
Atg5WT/lox

Metastasis


B

PAAD -TCGA
Atg5^{high} vs Atg5^{low}



Log-Rank Equal Curves p=0.08582
Hazard Ratio = 1.44 (conf. int. 0.95 ~ 2.19),
p=0.08761

PACA-AU-ICGC
Atg5^{high} vs Atg5^{low}



Log-Rank Equal Curves p=0.02897
Hazard Ratio = 1.52 (conf. int. 1.04 ~ 2.21),
p=0.03021